Form 4: Fennec Pharmaceuticals CEO Rostislav Raykov Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Fennec Pharmaceuticals CEO Rostislav Raykov reports the release of restriction from 29,167 common shares awarded on March 31, 2023, resulting in a total beneficial ownership of 316,638 shares.
Summary
- On April 1, 2024, Rostislav Raykov, CEO of Fennec Pharmaceuticals, had a transaction involving common shares.
- A restriction was released from 29,167 common shares that were awarded on March 31, 2023.
- Following this transaction, Raykov beneficially owns 316,638 common shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, indicating a neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive compensation and share ownership, common in the pharmaceutical industry.
Stakeholder Impact
- The change in beneficial ownership may have a minor impact on shareholders, reflecting executive compensation and alignment with company performance.
Key Dates
| Date | Description |
|---|---|
| 03/31/2023 | Date of original share award |
| 04/01/2024 | Date of transaction (release of restriction) |
| 04/03/2024 | Date of signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.